Catalog No.: PC-45885Not For Human Use, Lab Use Only.
Crizotinib (PF-02341066;PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM.
Crizotinib (PF-02341066, PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM.
Crizotinib (PF-02341066) displays >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB.
Crizotinib (PF-02341066) also inhibits ALK (IC50=24 nM), potently inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50=5-20 nM).
Crizotinib (PF-02341066) shows antitumor efficacy in tumor models at well-tolerated doses in vivo.
